JPRN-UMIN000032845已完成2 期
A randomized multi-center phase II study on the efficacy of postoperative Rikkunshito plus Elental in gastric cancer patients with adjuvant chemotherapy - A randomized multi-center phase II study on the efficacy of postoperative Rikkunshito plus Elental in gastric cancer patients with adjuvant chemotherapy
PO corporation Digestive Disorder Support Organization (DDSO)0 个研究点目标入组 100 人开始时间: 2018年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with another malignant neoplasm 2) Patients who received preoperative chemo- or radiotherapy 3) Patients with preoperative malnutrition (alb less than 3.0g per dl) 4) Patients who were administrated Kanpo 5) Patients with allergy of ELENTAL 6) Patients with history of Kanpo allergy 7) Patients with severe psychiatric disorder 8) Patients who was considered ineligible by the investigator
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate efficacy and safety of azacitidine alone or in combination with lenalidomide in patients with advanced cancer in bone marrow or in the blood with a defective chromosome 5EUCTR2011-001639-21-FIMDSG Nordic Myelodysplastic Syndrom Group72
进行中（未招募）
不适用
A randomized, multicenter, phase II study of the efficacy and safety of TRASTUZUMAB-MCC-DM1 vs. TRASTUZUMAB (HERCEPTIN) and DOCETAXEL (TAXOTERE) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease - NDHER2-positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-002819-40-ITROCHE120
进行中（未招募）
1 期
A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic diseaseHER2-positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-002819-40-ESF Hoffmann-La Roche Ltd120
进行中（未招募）
不适用
A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic diseaseEUCTR2008-002819-40-DEF. Hoffmann-La Roche Ltd120
进行中（未招募）
不适用
A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic diseaseHER2-positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-002819-40-HUF Hoffmann-La Roche Ltd120